{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T19:22:15Z","timestamp":1788376935280,"version":"build-2803163510"},"reference-count":63,"publisher":"BMJ","issue":"3","license":[{"start":{"date-parts":[[2022,3,2]],"date-time":"2022-03-02T00:00:00Z","timestamp":1646179200000},"content-version":"unspecified","delay-in-days":1,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"MINECO","award":["PID2020-112892RB-100"],"award-info":[{"award-number":["PID2020-112892RB-100"]}]},{"name":"MINECO","award":["SAF2017-83267-C2-1-R"],"award-info":[{"award-number":["SAF2017-83267-C2-1-R"]}]},{"DOI":"10.13039\/501100000780","name":"European Union","doi-asserted-by":"crossref","award":["635122"],"award-info":[{"award-number":["635122"]}],"id":[{"id":"10.13039\/501100000780","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100008530","name":"FEDER","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100008530","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Fundaci\u00f3n La Caixa"},{"name":"AECC"},{"DOI":"10.13039\/100007406","name":"Fundaci\u00f3n BBVA","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007406","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["J Immunother Cancer"],"accepted":{"date-parts":[[2022,1,12]]},"published-print":{"date-parts":[[2022,3]]},"abstract":"<jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>On the basis of efficacy in mouse tumor models, multiple CD137 (4-1BB) agonist agents are being preclinically and clinically developed. The costimulatory molecule CD137 is inducibly expressed as a transmembrane or as a soluble protein (sCD137). Moreover, the CD137 cytoplasmic signaling domain is a key part in approved chimeric antigen receptors (CARs). Reliable pharmacodynamic biomarkers for CD137 ligation and costimulation of T cells will facilitate clinical development of CD137 agonists in the clinic.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>We used human and mouse CD8 T cells undergoing activation to measure CD137 transcription and protein expression levels determining both the membrane-bound and soluble forms. In tumor-bearing mice plasma sCD137 concentrations were monitored on treatment with agonist anti-CD137 monoclonal antibodies (mAbs). Human CD137 knock-in mice were treated with clinical-grade agonist anti-human CD137 mAb (Urelumab). Sequential plasma samples were collected from the first patients intratumorally treated with Urelumab in the INTRUST clinical trial. Anti-mesothelin CD137-encompassing CAR-transduced T cells were stimulated with mesothelin coated microbeads. sCD137 was measured by sandwich ELISA and Luminex. Flow cytometry was used to monitor CD137 surface expression.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>CD137 costimulation upregulates transcription and protein expression of CD137 itself including sCD137 in human and mouse CD8 T cells. Immunotherapy with anti-CD137 agonist mAb resulted in increased plasma sCD137 in mice bearing syngeneic tumors. sCD137 induction is also observed in human CD137 knock-in mice treated with Urelumab and in mice transiently humanized with T cells undergoing CD137 costimulation inside subcutaneously implanted Matrigel plugs. The CD137 signaling domain-containing CAR T cells readily released sCD137 and acquired CD137 surface expression on antigen recognition. Patients treated intratumorally with low dose Urelumab showed increased plasma concentrations of sCD137.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>sCD137 in plasma and CD137 surface expression can be used as quantitative parameters dynamically reflecting therapeutic costimulatory activity elicited by agonist CD137-targeted agents.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1136\/jitc-2021-003532","type":"journal-article","created":{"date-parts":[[2022,3,2]],"date-time":"2022-03-02T11:05:48Z","timestamp":1646219148000},"page":"e003532","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":27,"title":["Soluble CD137 as a dynamic biomarker to monitor agonist CD137 immunotherapies"],"prefix":"10.1136","volume":"10","clinical-trial-number":[{"clinical-trial-number":"nct03792724","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct03792724","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8936-190X","authenticated-orcid":false,"given":"Javier","family":"Glez-Vaz","sequence":"first","affiliation":[{"name":"Program of Immunology and Immunotherapy, Center for Applied Medical Research (CIMA), Pamplona, Spain"},{"name":"Navarra Institute for Health Research (IDISNA), Pamplona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arantza","family":"Azpilikueta","sequence":"additional","affiliation":[{"name":"Program of Immunology and Immunotherapy, Center for Applied Medical Research (CIMA), Pamplona, Spain"},{"name":"Navarra Institute for Health Research (IDISNA), Pamplona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irene","family":"Olivera","sequence":"additional","affiliation":[{"name":"Program of Immunology and Immunotherapy, Center for Applied Medical Research (CIMA), Pamplona, Spain"},{"name":"Navarra Institute for Health Research (IDISNA), Pamplona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Assunta","family":"Cirella","sequence":"additional","affiliation":[{"name":"Program of Immunology and Immunotherapy, Center for Applied Medical Research (CIMA), Pamplona, Spain"},{"name":"Navarra Institute for Health Research (IDISNA), Pamplona, Spain"},{"name":"Departments of Immunology-Immunotherapy and Oncology, Cl\u00ednica Universidad de Navarra, Pamplona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7339-4464","authenticated-orcid":false,"given":"Alvaro","family":"Teijeira","sequence":"additional","affiliation":[{"name":"Program of Immunology and Immunotherapy, Center for Applied Medical Research (CIMA), Pamplona, Spain"},{"name":"Navarra Institute for Health Research (IDISNA), Pamplona, Spain"},{"name":"Centro de Investigaci\u00f3n Biom\u00e9dica en Red de C\u00e1ncer (CIBERONC), Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria C","family":"Ochoa","sequence":"additional","affiliation":[{"name":"Program of Immunology and Immunotherapy, Center for Applied Medical Research (CIMA), Pamplona, Spain"},{"name":"Navarra Institute for Health Research (IDISNA), Pamplona, Spain"},{"name":"Departments of Immunology-Immunotherapy and Oncology, Cl\u00ednica Universidad de Navarra, Pamplona, Spain"},{"name":"Centro de Investigaci\u00f3n Biom\u00e9dica en Red de C\u00e1ncer (CIBERONC), Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5969-9181","authenticated-orcid":false,"given":"Maite","family":"Alvarez","sequence":"additional","affiliation":[{"name":"Program of Immunology and Immunotherapy, Center for Applied Medical Research (CIMA), Pamplona, Spain"},{"name":"Navarra Institute for Health Research (IDISNA), Pamplona, Spain"},{"name":"Departments of Immunology-Immunotherapy and Oncology, Cl\u00ednica Universidad de Navarra, Pamplona, Spain"},{"name":"Centro de Investigaci\u00f3n Biom\u00e9dica en Red de C\u00e1ncer (CIBERONC), Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1581-3728","authenticated-orcid":false,"given":"I\u00f1aki","family":"Eguren-Santamaria","sequence":"additional","affiliation":[{"name":"Program of Immunology and Immunotherapy, Center for Applied Medical Research (CIMA), Pamplona, Spain"},{"name":"Navarra Institute for Health Research (IDISNA), Pamplona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlos","family":"Luri-Rey","sequence":"additional","affiliation":[{"name":"Program of Immunology and Immunotherapy, Center for Applied Medical Research (CIMA), Pamplona, Spain"},{"name":"Navarra Institute for Health Research (IDISNA), Pamplona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria E","family":"Rodriguez-Ruiz","sequence":"additional","affiliation":[{"name":"Program of Immunology and Immunotherapy, Center for Applied Medical Research (CIMA), Pamplona, Spain"},{"name":"Navarra Institute for Health Research (IDISNA), Pamplona, Spain"},{"name":"Departments of Immunology-Immunotherapy and Oncology, Cl\u00ednica Universidad de Navarra, Pamplona, Spain"},{"name":"Centro de Investigaci\u00f3n Biom\u00e9dica en Red de C\u00e1ncer (CIBERONC), Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinxin","family":"Nie","sequence":"additional","affiliation":[{"name":"Department of Immunobiology, Yale University School of Medicine, New Haven, Connecticut, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lieping","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Immunobiology, Yale University School of Medicine, New Haven, Connecticut, USA"},{"name":"Department of Medicine (Medical Oncology), Yale University School of Medicine, New Haven, Connecticut, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sonia","family":"Guedan","sequence":"additional","affiliation":[{"name":"Department of Hematology and Oncology, Hospital Clinic. Institut d'Investigacions Biom\u00e8diques August Pi i Sunyer (IDIBAPS), Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miguel F","family":"Sanmamed","sequence":"additional","affiliation":[{"name":"Program of Immunology and Immunotherapy, Center for Applied Medical Research (CIMA), Pamplona, Spain"},{"name":"Navarra Institute for Health Research (IDISNA), Pamplona, Spain"},{"name":"Departments of Immunology-Immunotherapy and Oncology, Cl\u00ednica Universidad de Navarra, Pamplona, Spain"},{"name":"Centro de Investigaci\u00f3n Biom\u00e9dica en Red de C\u00e1ncer (CIBERONC), Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jose","family":"Luis Perez Gracia","sequence":"additional","affiliation":[{"name":"Program of Immunology and Immunotherapy, Center for Applied Medical Research (CIMA), Pamplona, Spain"},{"name":"Navarra Institute for Health Research (IDISNA), Pamplona, Spain"},{"name":"Departments of Immunology-Immunotherapy and Oncology, Cl\u00ednica Universidad de Navarra, Pamplona, Spain"},{"name":"Centro de Investigaci\u00f3n Biom\u00e9dica en Red de C\u00e1ncer (CIBERONC), Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1360-348X","authenticated-orcid":false,"given":"Ignacio","family":"Melero","sequence":"additional","affiliation":[{"name":"Program of Immunology and Immunotherapy, Center for Applied Medical Research (CIMA), Pamplona, Spain"},{"name":"Navarra Institute for Health Research (IDISNA), Pamplona, Spain"},{"name":"Departments of Immunology-Immunotherapy and Oncology, Cl\u00ednica Universidad de Navarra, Pamplona, Spain"},{"name":"Centro de Investigaci\u00f3n Biom\u00e9dica en Red de C\u00e1ncer (CIBERONC), Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2022,3,2]]},"reference":[{"key":"2025100310441523000_10.3.e003532.1","doi-asserted-by":"publisher","DOI":"10.1038\/nri1148"},{"key":"2025100310441523000_10.3.e003532.2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.86.6.1963"},{"key":"2025100310441523000_10.3.e003532.3","doi-asserted-by":"crossref","first-page":"771","DOI":"10.4049\/jimmunol.150.3.771","article-title":"Inducible T cell antigen 4-1BB. Analysis of expression and function","volume":"150","author":"Pollok","year":"1993","journal-title":"J Immunol"},{"key":"2025100310441523000_10.3.e003532.4","doi-asserted-by":"publisher","DOI":"10.1084\/jem.186.1.47"},{"key":"2025100310441523000_10.3.e003532.5","doi-asserted-by":"publisher","DOI":"10.1006\/cimm.1998.1396"},{"key":"2025100310441523000_10.3.e003532.6","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.0901619"},{"key":"2025100310441523000_10.3.e003532.7","doi-asserted-by":"publisher","DOI":"10.1038\/cmi.2010.82"},{"key":"2025100310441523000_10.3.e003532.8","doi-asserted-by":"publisher","DOI":"10.1016\/j.tips.2008.05.005"},{"key":"2025100310441523000_10.3.e003532.9","doi-asserted-by":"publisher","DOI":"10.1002\/eji.1830231037"},{"key":"2025100310441523000_10.3.e003532.10","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1002\/(SICI)1521-4141(199803)28:03<1116::AID-IMMU1116>3.0.CO;2-A","article-title":"Amplification of tumor immunity by gene transfer of the co-stimulatory 4-1BB ligand synergy with the CD28 co-stimulatory 4-1BB ligand: synergy with the CD28 co-stimulatory pathway","volume":"23","author":"Melero","year":"1998","journal-title":"Eur J Immunol"},{"key":"2025100310441523000_10.3.e003532.11","doi-asserted-by":"crossref","first-page":"3360","DOI":"10.4049\/jimmunol.155.7.3360","article-title":"Potential role of 4-1BB in T cell activation. Comparison with the costimulatory molecule CD28","volume":"155","author":"Hurtado","year":"1995","journal-title":"J Immunol"},{"key":"2025100310441523000_10.3.e003532.12","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-17-0767"},{"key":"2025100310441523000_10.3.e003532.13","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20171068"},{"key":"2025100310441523000_10.3.e003532.14","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20160485"},{"key":"2025100310441523000_10.3.e003532.15","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-17-0159"},{"key":"2025100310441523000_10.3.e003532.16","doi-asserted-by":"crossref","first-page":"4833","DOI":"10.4049\/jimmunol.163.9.4833","article-title":"Analysis of 4-1BB ligand (4-1BBL)-deficient mice and of mice lacking both 4-1BBL and CD28 reveals a role for 4-1BBL in skin allograft rejection and in the cytotoxic T cell response to influenza virus","volume":"163","author":"DeBenedette","year":"1999","journal-title":"J Immunol"},{"key":"2025100310441523000_10.3.e003532.17","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20190678"},{"key":"2025100310441523000_10.3.e003532.18","doi-asserted-by":"crossref","first-page":"1510","DOI":"10.1182\/blood.2019000644","article-title":"CD137 deficiency causes immune dysregulation with predisposition to lymphomagenesis","volume":"134","author":"Somekh","year":"2019","journal-title":"Blood"},{"key":"2025100310441523000_10.3.e003532.19","doi-asserted-by":"publisher","DOI":"10.1038\/nm0697-682"},{"key":"2025100310441523000_10.3.e003532.20","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1158\/0008-5472.1089.65.3","article-title":"Blockade of B7-H1 and PD-1 by monoclonal antibodies potentiates cancer therapeutic immunity","volume":"65","author":"Hirano","year":"2005","journal-title":"Cancer Res"},{"key":"2025100310441523000_10.3.e003532.21","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2016.01.013"},{"key":"2025100310441523000_10.3.e003532.22","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-08-0993"},{"key":"2025100310441523000_10.3.e003532.23","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-08-1365"},{"key":"2025100310441523000_10.3.e003532.24","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-16-0549"},{"key":"2025100310441523000_10.3.e003532.25","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-16-1272"},{"key":"2025100310441523000_10.3.e003532.26","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-012-1237-1"},{"key":"2025100310441523000_10.3.e003532.27","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-17-1922"},{"key":"2025100310441523000_10.3.e003532.28","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-06-741041"},{"key":"2025100310441523000_10.3.e003532.29","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-019-10088-1","article-title":"Optimization of 4-1BB antibody for cancer immunotherapy by balancing agonistic strength with FcgammaR affinity","volume":"10","author":"Qi","year":"2019","journal-title":"Nat Commun"},{"key":"2025100310441523000_10.3.e003532.30","doi-asserted-by":"publisher","DOI":"10.1136\/esmoopen-2020-000733"},{"key":"2025100310441523000_10.3.e003532.31","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aav5989"},{"key":"2025100310441523000_10.3.e003532.32","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-18-3654"},{"key":"2025100310441523000_10.3.e003532.33","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-19-2958"},{"key":"2025100310441523000_10.3.e003532.34","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-021-26645-6","article-title":"Cancer immune therapy with PD-1-dependent CD137 co-stimulation provides localized tumour killing without systemic toxicity","volume":"12","author":"Qiao","year":"2021","journal-title":"Nat Commun"},{"key":"2025100310441523000_10.3.e003532.35","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-20-0328"},{"key":"2025100310441523000_10.3.e003532.36","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2025930118"},{"key":"2025100310441523000_10.3.e003532.37","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-021-27613-w","article-title":"CD137 (4-1BB) costimulation of CD8+ T cells is more potent when provided in cis than in trans with respect to CD3-TCR stimulation","volume":"12","author":"Otano","year":"2021","journal-title":"Nat Commun"},{"key":"2025100310441523000_10.3.e003532.38","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1203010"},{"key":"2025100310441523000_10.3.e003532.39","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.omtm.2018.11.010","article-title":"Development of a novel anti-CD19 chimeric antigen receptor: a paradigm for an affordable CAR T cell production at academic institutions","volume":"12","author":"Castella","year":"2019","journal-title":"Mol Ther Methods Clin Dev"},{"key":"2025100310441523000_10.3.e003532.40","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2015.1062967","article-title":"Hypoxia-induced soluble CD137 in malignant cells blocks CD137L-costimulation as an immune escape mechanism","volume":"5","author":"Labiano","year":"2016","journal-title":"Oncoimmunology"},{"key":"2025100310441523000_10.3.e003532.41","doi-asserted-by":"publisher","DOI":"10.1053\/j.seminoncol.2010.09.013"},{"key":"2025100310441523000_10.3.e003532.42","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.164.4.2160"},{"key":"2025100310441523000_10.3.e003532.43","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-010-0846-9"},{"key":"2025100310441523000_10.3.e003532.44","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-10-2880"},{"key":"2025100310441523000_10.3.e003532.45","doi-asserted-by":"publisher","DOI":"10.1038\/nm.3838"},{"key":"2025100310441523000_10.3.e003532.46","doi-asserted-by":"publisher","DOI":"10.1172\/JCI73639"},{"key":"2025100310441523000_10.3.e003532.47","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-018-0040-8"},{"key":"2025100310441523000_10.3.e003532.48","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-16-0364"},{"key":"2025100310441523000_10.3.e003532.49","doi-asserted-by":"crossref","DOI":"10.4161\/onci.25581","article-title":"Continuous 4-1BB co-stimulatory signals for the optimal expansion of tumor-infiltrating lymphocytes for adoptive T-cell therapy","volume":"2","author":"Chacon","year":"2013","journal-title":"Oncoimmunology"},{"key":"2025100310441523000_10.3.e003532.50","doi-asserted-by":"publisher","DOI":"10.1097\/CJI.0b013e318209e7ec"},{"key":"2025100310441523000_10.3.e003532.51","doi-asserted-by":"publisher","DOI":"10.1002\/eji.201445388"},{"key":"2025100310441523000_10.3.e003532.52","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aax4738"},{"key":"2025100310441523000_10.3.e003532.53","doi-asserted-by":"publisher","DOI":"10.1016\/0378-1119(95)00349-B"},{"key":"2025100310441523000_10.3.e003532.54","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1521-4141(199801)28:01<290::AID-IMMU290>3.0.CO;2-S"},{"key":"2025100310441523000_10.3.e003532.55","doi-asserted-by":"crossref","DOI":"10.3390\/ijms22052730","article-title":"Role of ADAM10 and ADAM17 in regulating CD137 function","volume":"22","author":"Seidel","year":"2021","journal-title":"Int J Mol Sci"},{"key":"2025100310441523000_10.3.e003532.56","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1002\/JLB.2MR1119-224R","article-title":"The relevance of soluble CD137 in the regulation of immune responses and for immunotherapeutic intervention","volume":"107","author":"Luu","year":"2020","journal-title":"J Leukoc Biol"},{"key":"2025100310441523000_10.3.e003532.57","doi-asserted-by":"publisher","DOI":"10.1016\/j.molimm.2008.05.028"},{"key":"2025100310441523000_10.3.e003532.58","doi-asserted-by":"publisher","DOI":"10.1016\/S0014-5793(03)00326-0"},{"key":"2025100310441523000_10.3.e003532.59","doi-asserted-by":"publisher","DOI":"10.1189\/jlb.0510315"},{"key":"2025100310441523000_10.3.e003532.60","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.coi.2021.02.010","article-title":"Mechanisms of response and resistance to CAR T cell therapies","volume":"69","author":"Berger","year":"2021","journal-title":"Curr Opin Immunol"},{"key":"2025100310441523000_10.3.e003532.61","doi-asserted-by":"publisher","DOI":"10.1126\/science.aar6711"},{"key":"2025100310441523000_10.3.e003532.62","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-SITC2020.0658"},{"key":"2025100310441523000_10.3.e003532.63","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-SITC2020.0730"}],"container-title":["Journal for ImmunoTherapy of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/jitc-2021-003532","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T17:44:28Z","timestamp":1759513468000},"score":1,"resource":{"primary":{"URL":"https:\/\/jitc.bmj.com\/lookup\/doi\/10.1136\/jitc-2021-003532"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3]]},"references-count":63,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2022,3,2]]},"published-print":{"date-parts":[[2022,3]]}},"alternative-id":["10.1136\/jitc-2021-003532"],"URL":"https:\/\/doi.org\/10.1136\/jitc-2021-003532","relation":{},"ISSN":["2051-1426"],"issn-type":[{"value":"2051-1426","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,3]]}}}